GC Pharma plans to develop what it intends to be the world’s first blood plasma treatment for COVID-19, with a goal to commercialize the product in the latter half of this year.
GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy
Korean Firm Plans Trial Start Soon
A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.
